Skip to content

SCIENCE & EVIDENCE

Evidence.

Presented by source, development stage and evidentiary weight.

Technical characterization, direct D016 preclinical findings, external scientific context and regulatory-development interactions are kept distinct. Preclinical findings are not presented as clinical efficacy.

CRL PRECLINICAL STUDY  ↓ D016 TECHNOLOGY  →
D016EVIDENCE
TECHNICAL PRECLINICAL REGULATORY CLINICAL
NOT YET ESTABLISHED

EVIDENCE ARCHITECTURE

Different Sources. Different Evidentiary Weight.

The scientific record is organized according to what each source can – and cannot – establish.

01DIRECT TECHNICAL EVIDENCE

D016 analytical and biochemical characterization.

02DIRECT PRECLINICAL EVIDENCE

Charles River LDLR−/− mouse proof-of-concept study with D016.

03REGULATORY-DEVELOPMENT EVIDENCE

BfArM Scientific Advice interactions informing the development plan.

04EXTERNAL MECHANISTIC / IN-VIVO CONTEXT

Published work with other hyaluronan-degrading enzymes; not D016 evidence.

05HISTORICAL HUMAN OBSERVATIONS

Uncontrolled off-label observations with bovine hyaluronidase; hypothesis-generating only.

06CLINICAL BELACT EVIDENCE

Not yet established. Future clinical evidence requires the applicable clinical development program.

DIRECT D016 PRECLINICAL EVIDENCE

Exploratory LDLR-Mouse Proof-of-Concept

Charles River Laboratories · Non-GLP Abbreviated Report · Study No. 20238304 · Sponsor reference HSE D016 001 PoC

MODELLDLR-/-mouse

Male JAX 002207 mice, approximately 9–11 weeks old, with diet-induced atherosclerosis after approximately 12 weeks of cholesterol-containing Western Diet.

PRIMARY D016-ALONE GROUPSn=12 per group

Vehicle, 7,500 U/kg/day and 750,000 U/kg/day. The full study comprised seven groups; the primary D016-alone comparison was G2–G4.

TREATMENTIV · once daily · Days 1–10

Ten consecutive treatment days followed by a 19-day treatment-free interval to terminal assessment on Day 29.

PRIMARY ENDPOINTAortic-root lesion area

Total histological aortic-root lesion area on Day 29, quantified from H&E-stained cryosections using five step levels and computer-assisted image analysis.

OBSERVED LESION-AREA RESULT

High Dose Was Associated With a Smaller Lesion Area Than Vehicle.

The low-dose group was essentially unchanged versus vehicle. The high-dose group showed an 18.8% lower mean aortic-root lesion area versus vehicle at Day 29.

Boundary: exploratory non-GLP animal evidence; not clinical efficacy.

STUDY CONDUCT · CROCharles River LaboratoriesCardiovascular / Metabolic Disease Studies
VEHICLE2,514,408± 119,703 µm²
LOW DOSE · 7,500 U/kg/day2,502,474± 138,252 µm²
HIGH DOSE · 750,000 U/kg/day2,042,619± 126,841 µm²18.8% below vehicle
ORIGINAL CRL ANALYSISOne-way ANOVA G1–G4: F(3,44)=13.29; P<0.0001
DUNNETT VS VEHICLELow dose P=0.9999 · High dose P=0.0431

The Day-1 no-treatment group was a non-contemporaneous baseline/reference arm and not the concurrent vehicle control. Statistical values shown above reproduce the original CRL Appendix-6 analysis.

INTERPRETATION & OPEN QUESTIONS

Proof-of-Concept, Not Clinical Proof.

01

OBSERVED FINDING

In this exploratory study, 750,000 U/kg/day for 10 days was associated with a smaller aortic-root lesion area on Day 29 versus vehicle. The low dose showed no difference.

02

DOSE–RESPONSE / EXPOSURE

A dose–response relationship was not established. Pharmacokinetic and exposure characterization were not part of this proof-of-concept study and remain development questions.

03

TRANSLATIONAL BOUNDARY

The result does not establish safety or efficacy in humans and does not predict clinical benefit. Translation requires the applicable nonclinical, clinical and regulatory program.

EXTERNAL SCIENTIFIC CONTEXT

Mechanistic Context Is Not D016 Evidence.

External studies can support biological plausibility or historical context, but they are not interchangeable with direct evidence generated with D016.

PUBLISHED · EXTERNAL

Ozegowski et al. · WHHL Rabbit / Human Plaque Work

A 2008 publication investigated a microbial hyaluronate lyase from Streptococcus agalactiae in isolated human atherosclerotic plaque tissue and in WHHL rabbits. Repeated intravenous administration in rabbits was reported with a tendency toward reduced plaque formation; the authors called for further investigation in larger, more controlled animal groups.

Evidence boundary: different enzyme and study system. External mechanistic / in-vivo precedent only; not evidence of D016 efficacy.

Ozegowski J-H et al. Pharmazie. 2008;63:601–605. doi:10.1691/ph.2008.8554.

HISTORICAL · HYPOTHESIS-GENERATING

Burgard · Off-Label Human Observations

The available manuscript describes several historical off-label cases in which bovine-derived hyaluronidase was administered intravenously and outcomes were assessed with clinical and imaging methods.

Evidence boundary: uncontrolled observations, different enzyme source, no prospective controlled D016 study. These observations are not used to substantiate BELACT efficacy.

Available source: G.M. Burgard, “Dissolving atherosclerotic plaques with high doses of intravenous hyaluronidase in CHD or AOD.” Publication status is not established from the source document available to Pharmact.

REGULATORY-DEVELOPMENT EVIDENCE

Scientific Advice Informs the Development Plan.

BfArM Scientific Advice discussions addressed the nonclinical and initial clinical development strategy. The documented 2021 interaction included short-term 14-day repeat-dose toxicology in two species, pharmacokinetic/toxicokinetic considerations and an initial clinical dose-finding study in healthy volunteers using SAD/MAD before patient studies.

Regulatory context. Scientific Advice is a regulatory interaction and development-planning input. It is not an authorization, approval, designation or confirmation of safety or efficacy.

EVIDENCE BOUNDARY

D016 and BELACT remain in development. The evidence shown here must be interpreted according to its source and development stage. Animal, ex-vivo, historical observational and regulatory-development information does not establish clinical safety or efficacy.

SCIENCE & DEVELOPMENT

Explore the D016 Technology and BELACT Program

Scientific evidence is evaluated together with technology characterization, nonclinical development and the intended regulatory pathway.

D016 TECHNOLOGYBELACT PROGRAM